[Results of clinical trials of a new antitubercular agent, terizidone (Terivalidine)].
D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003523:Cycloserine / Q000009:adverse effects / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007097:Imines / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014202:Tremor / Q000139:chemically induced; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014717:Vertigo / Q000139:chemically induced
D000995:Antitubercular Agents; D007097:Imines; D010080:Oxazoles; D003523:Cycloserine
Rezultati klinickog ispitivanja novog antituberkulotika terizidona (Terivalidina.